NASDAQ · ENLV
Enlivex Therapeutics Ltd.
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
Loading market information…
TLV · CANF.TA · ILA
Stock price, earnings
Quote as of Oct 30, 2026, 08:22 AM UTC. Cached market data; not a live quote.
One-year closing-price history · ILA. Historical prices are not a forecast.
Can-Fite BioPharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 91.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Can-Fite BioPharma Ltd.’s next earnings report is currently expected on Apr 1, 2027, with estimated earnings per share of -ILA 1.25. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Can-Fite BioPharma Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.
Latest available per-share figures in ILS. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 | Nov 29, 2024 | -ILA 0.000.0% vs estimate | ILA 1.12M+100.0% vs estimate |
|---|
| Q2 2024 | Aug 29, 2024 | -ILA 0.00-200.72% vs estimate | ILA 377.92K-66.67% vs estimate |
|---|
| Q1 2024 | Jun 26, 2024 | -ILA 0.00+99.71% vs estimate | ILA 1.11M0.0% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
₪2.50+₪0.05 (+1.87%)
Matricelf Ltd.’s quoted price sits in the lower half of its reported 52-week range, 70.68% below the high.
₪0.23+₪0.00 (+1.32%)
Clal Biotechnology Industries Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.11% below the high.
₪1.99+₪0.14 (+7.46%)
Together Pharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.13% below the high.
₪0.01₪0.00 (0.0%)
BioLineRx Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.62% below the high.
₪0.01₪0.00 (0.0%)
Purple Biotech Ltd.’s quoted price sits in the upper half of its reported 52-week range, 41.18% below the high.
₪3.13+₪0.15 (+5.18%)
BioLight Life Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.9% below the high.
₪1.59-₪0.04 (-2.27%)
Identi Healthcare Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.96% below the high.